Literature DB >> 28275743

Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer.

Caterina Vivaldi1, Alfredo Falcone1, Lorenzo Fornaro1.   

Abstract

Entities:  

Year:  2017        PMID： 28275743      PMCID： PMC5334553          DOI： 10.21037/tgh.2017.02.01

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  18 in total

Review 1.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

2.  Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Authors:  Nick Pavlakis; Katrin M Sjoquist; Andrew J Martin; Eric Tsobanis; Sonia Yip; Yoon-Koo Kang; Yung-Jue Bang; Thierry Alcindor; Christopher J O'Callaghan; Margot J Burnell; Niall C Tebbutt; Sun Young Rha; Jeeyun Lee; Jae-Yong Cho; Lara R Lipton; Mark Wong; Andrew Strickland; Jin Won Kim; John R Zalcberg; John Simes; David Goldstein
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 3.  The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.

Authors:  Emil Ter Veer; Nadia Haj Mohammad; Gert van Valkenhoef; Lok Lam Ngai; Rosa M A Mali; Maarten C Anderegg; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  J Natl Cancer Inst       Date:  2016-08-30       Impact factor: 13.506

Review 4.  Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.

Authors:  Markus Moehler; Maike Delic; Katrin Goepfert; Daniela Aust; Heike I Grabsch; Niels Halama; Bernd Heinrich; Catherine Julie; Florian Lordick; Manfred P Lutz; Murielle Mauer; Maria Alsina Maqueda; Hansjoerg Schild; Carl C Schimanski; Anna-Dorothea Wagner; Arnaud Roth; Michel Ducreux
Journal:  Eur J Cancer       Date:  2016-03-31       Impact factor: 9.162

5.  Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Authors:  Jin Li; Shukui Qin; Jianming Xu; Jianping Xiong; Changping Wu; Yuxian Bai; Wei Liu; Jiandong Tong; Yunpeng Liu; Ruihua Xu; Zhehai Wang; Qiong Wang; Xuenong Ouyang; Yan Yang; Yi Ba; Jun Liang; Xiaoyan Lin; Deyun Luo; Rongsheng Zheng; Xin Wang; Guoping Sun; Liwei Wang; Leizhen Zheng; Hong Guo; Jingbo Wu; Nong Xu; Jianwei Yang; Honggang Zhang; Ying Cheng; Ningju Wang; Lei Chen; Zhining Fan; Piaoyang Sun; Hao Yu
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

6.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

7.  Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Authors:  Axel Grothey; Suzanne George; Eric van Cutsem; Jean-Yves Blay; Alberto Sobrero; George D Demetri
Journal:  Oncologist       Date:  2014-05-12

8.  Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Authors:  H H Yoon; J C Bendell; F S Braiteh; I Firdaus; P A Philip; A L Cohn; N Lewis; D M Anderson; E Arrowsmith; J D Schwartz; L Gao; Y Hsu; Y Xu; D Ferry; S R Alberts; Z A Wainberg
Journal:  Ann Oncol       Date:  2016-10-20       Impact factor: 51.769

Review 9.  Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.

Authors:  Emil Ter Veer; Nadia Haj Mohammad; Gert van Valkenhoef; Lok Lam Ngai; Rosa M A Mali; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

10.  Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward.

Authors:  Lorenzo Fornaro; Enrico Vasile; Alfredo Falcone
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.